Related references
Note: Only part of the references are listed.Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma
Hideo Kunimoto et al.
ONCOLOGY (2020)
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2019)
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma
Nina M. Munoz et al.
MAGNETIC RESONANCE IMAGING (2019)
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
Hidekatsu Kuorda et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response?
Hasmik Koulakian et al.
EUROPEAN RADIOLOGY (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up
Sascha Kaufmann et al.
ACTA RADIOLOGICA (2018)
Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography
Kazue Shiozawa et al.
JOURNAL OF MEDICAL ULTRASONICS (2017)
Central vascular structures as a characteristic finding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US
Kazuya Sugimori et al.
JOURNAL OF MEDICAL ULTRASONICS (2017)
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
Masatoshi Kudo et al.
LIVER CANCER (2016)
Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma
Kazushi Numata et al.
EUROPEAN JOURNAL OF RADIOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound
Maria Assunta Zocco et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US
Katsutoshi Sugimoto et al.
LIVER INTERNATIONAL (2013)
Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation
Clemens C. Cyran et al.
PLOS ONE (2013)
Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy
Jian Ang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma
Min Ju Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification-Preliminary Results
Nathalie Lassau et al.
RADIOLOGY (2011)
Focal Hypoechoic Tumors of Fatty Liver Characterization of Conventional and Contrast-Enhanced Ultrasonography
Li-Ping Liu et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2009)
Early Antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
ONCOLOGIST (2008)
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib:: Pilot study using dynamic contrast-enhanced Doppler ultrasound
Michele Lamuraglia et al.
EUROPEAN JOURNAL OF CANCER (2006)
Share Paper
